ClinicalTrials.gg
CompletedNCT04364620Updated Apr 6, 2025Results posted

AB-16B5 Combined With Docetaxel in Subjects With Metastatic Non-Small Cell Lung Cancer (EGIA-002)

A Phase 2 interventional study of AB-16B5 and Docetaxel in NSCLC Stage IV, sponsored by Alethia Biotherapeutics. Completed at 5 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-06.

Sponsored by Alethia Biotherapeutics · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
35
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 661 studies in Carcinoma, Non-Small-Cell Lung with a site in Canada — 108 open to participants now, 231 under way, 98 of them phase 3. Carcinoma, Non-Small-Cell Lung · Canada.

Enrollment
522nd of 614
35 · median 190
Started
2021
with 37 others
Phase 2
165 of 661
16 open now
Registered
443rd of 661
by date

Among the 661 studies in Carcinoma, Non-Small-Cell Lung with a site in Canada, this one is the 522nd largest by enrollment of the 614 interventional ones that give a count, is one of 38 that started in 2021, is one of 165 in phase 2, and was the 443rd registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

108 of the 661 studies in Carcinoma, Non-Small-Cell Lung with a site in Canada are open now. Recruiting first, the newest first:

103 more — sign in →

All 108 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 661 studies in Carcinoma, Non-Small-Cell Lung with a site in Canada, or all of them as a file.
02

Study summary

This Phase II study will recruit 40 metastatic non-small cell lung cancer patients who failed treatment with a platinum-containing doublet treatment and an anti-PD1 or PD-L1 immune checkpoint antibody, administered simultaneously or sequentially. All recruited patients will receive AB-16B5 at a dose of 12 mg/kg once weekly combined with docetaxel at a dose of 75 mg/m2 once every 3 weeks.

Read the detailed description

This is an open-label, single-arm, multi-center Phase II trial of AB-16B5 in combination with docetaxel in previously treated subjects with metastatic non-small cell lung cancer who have experienced disease progression following treatment with a platinum-containing doublet treatment and an anti-PD1 or PD-L1 immune checkpoint antibody, administered simultaneously or sequentially. Approximately 40 subjects will be enrolled in this trial and receive AB-16B5 at a dose of 12 mg/kg once weekly on Days 1, 8 and 15 combined with docetaxel at a dose of 75 mg/m2 once every 3 weeks on Day 1. One cycle of treatment will consist of 21 days (3 weeks). The safety profile of the AB-16B5 and docetaxel combination will be examined during a safety lead-in period with the first 8 subjects completing one cycle of treatment. No dose escalation will be performed but a decision to de-escalate the AB-16B5 dose could be made using the modified toxicity probability interval method.

Subjects will be evaluated every 6 weeks with radiographic imaging to assess response to treatment using Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria for determination of the objective response rate (ORR) and progression free survival (PFS). Paired tumor biopsies (pre-treatment and on-treatment) will be collected in all subjects. Study treatment will continue until there is evidence of disease progression, treatment-related adverse events of unacceptable severity, subject request for discontinuation or Investigator determination that further treatment is not in the subject's best interest. Treatment through progression will be allowed if the Investigator considers the subject to be clinically stable. Subjects who must discontinue docetaxel due to toxicity will continue on AB-16B5.

03

Conditions studied

  • NSCLC Stage IV

Keywords

  • Lung cancer
  • Chemotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects (male or non-pregnant female) must be ≥ 18 years of age on the day of signing the .
  • Subjects with a or cytologically confirmed diagnosis of (Stage III-IV) non-small cell lung cancer (NSCLC) and with at least one defined by 1.1.
  • Subjects must have experienced a disease progression following treatment with an anti-PD1 or immune checkpoint antibody and a platinum-containing doublet treatment, administered simultaneously or sequentially.
  • Subjects with a targetable driver mutation in EGFR or ALK gene will be allowed on trial after failing all available targeted therapies and having experienced a disease progression following treatment with an anti-PD1 or PD-L1 immune checkpoint antibody and a platinum-containing doublet treatment, administered simultaneously or sequentially.
  • Subjects must have adequate organ and immune function
  • Subjects must have a tumor lesion amenable for with no for biopsy.
  • Subjects must have an (ECOG) performance status of ≤ 2.
  • Subjects must have a of at least 3 months.
  • Subjects must have recovered from the toxic effects resulting from the most recent cancer treatment to Grade 1 or less. If the subjects underwent major surgery or received radiation therapy, they must have recovered from the complications and/or toxicity.
  • Female subjects of must have a negative serum pregnancy test within 72 hours prior to the first dose of study treatment.
  • Subjects (both male and female) of must be willing to practice highly effective methods of throughout the study and for up to 90 days after the last dose of study medication. Abstinence is acceptable if this is the subject's usual lifestyle.
  • Female subjects are not considered of childbearing potential if they have a history of surgical sterility or evidence of status defined as any of the following:

    • ≥ 45 years of age and has not had menses for more than 2 years.
    • Amenorrhoeic for less than 2 years without hysterectomy and oophorectomy and a follicle stimulating hormone (FSH) value in the postmenopausal range at screening.
    • Post hysterectomy, oophorectomy or tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or by ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure.
  • Subjects must understand and be able and willing and likely to fully comply with the study procedures, including scheduled follow-up, and restrictions.
  • Subjects must have given written personally signed and dated informed consent to participate in the study in accordance with the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) Guidelines, before completing any study related procedures.

Exclusion criteria

Exclusion Criteria:

  • Subjects who have received prior therapy with AB-16B5.
  • Subjects who have received prior therapy with docetaxel for the treatment of NSCLC.
  • Subjects who are currently participating or has participated in a study of an agent or using an investigational device within 21 days prior to the first dose of study treatment. The 21-day window should be calculated using the last dose of an antineoplastic investigational agent or last use of an investigational device with antineoplastic intent.
  • Subjects who have received any anti-cancer treatment within 3 weeks or radiation therapy within 2 weeks prior to receiving the first dose of study treatment or who have not recovered from adverse events to Grade 1 or less. Subjects with alopecia are eligible to participate.
  • Subjects who are expected to require any other form of systemic or localized antineoplastic therapy while on the trial. This includes maintenance therapy with another agent or radiation therapy.
  • Subjects who are receiving a dose > 10 mg/day of prednisone (or equivalent) within 7 days prior to the first dose of study treatment or any other form of medication ( pre-treatment and/or post-treatment of docetaxel is allowed).
  • Subjects who require treatment with a strong inhibitor (e.g., ketoconazole, itraconazole, clarithromycin, atazanavir, indinavir, nefazodone, nelfinavir, ritonavir, saquinavir, telithromycin and voriconazole). Subjects may be included if there is an alternate treatment with a weak CYP3A4 inhibitor and they are willing to change at least 7 days prior to the first dose of study treatment.
  • Subjects who have another that is progressing or requires active treatment. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin or in situ cervical cancer.
  • Subjects who have known active central nervous system and/or carcinomatous meningitis. Subjects with previously treated may participate if they have been clinically stable for at least 2 weeks prior to the first dose of study treatment, if they have no evidence of new or enlarging brain metastases and if they are not receiving a dose > 10 mg/day of prednisone (or equivalent) within 7 days prior to the first dose of study treatment.
  • Subjects with abnormalities.
  • Subjects who have received or will receive a within 30 days prior to the first dose of study treatment.
  • Subjects with a known history of human immunodeficiency ().
  • Subjects with an active or C infection.
  • Subjects with an active infection requiring antibiotic therapy.
  • Subjects with a known history of alcohol or other substance abuse within the last year.
  • Subjects with known to docetaxel.
  • Subjects who have a history or current evidence of any condition, therapy or laboratory abnormalities that may confound the results of the trial, interfere with the subject's participation for the full duration of the trial or if it is not in the best interest of the subject to participate in the trial.
  • Subjects with medical, social or psychosocial factors that, in the opinion of the treating Investigator, could impact the safety or compliance with study procedures.
  • Subjects who are pregnant or lactating or who are expecting to conceive or father children within the projected duration of the trial through 90 days after the last dose of AB-16B5 or the last dose of docetaxel.
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
35 participants (actual)

Study arms

  • Experimental
    Arm AB-16B5 and Docetaxel

    AB-16B5 at a dose of 12 mg/kg once weekly on Days 1, 8 and 15 combined with docetaxel at a dose of 75 mg/m2 once every 3 weeks on Day 1.

    Drug: AB-16B5 · Drug: Docetaxel

Interventions

  • AB-16B5 is an inhibitor of the epithelial to mesenchymal transition. It is a fully humanized monoclonal antibody of IgG2 isotype against tumor-associated secreted clusterin (TA-sCLU).

  • Docetaxel is an anticancer chemotherapy drug approved in the treatment of non-small cell lung cancer

06

What researchers measure

Primary outcomes

  1. Objective Response Rate (ORR)

    Objective response rate (ORR) was defined as the percent of subjects documented to have a confirmed complete response (CR) or partial response (PR) as per RECIST 1.1 where Complete Response (CR): disappearance of all target lesions; Partial Response (PR): at least a 30% decrease in the sum of diameters of target lesions.

    Time frame: Every 6 weeks until the date of objectively documented progression for up to 2 years.

Secondary outcomes

  1. Clinical Benefit Rate (CBR)

    Clinical benefit rate (CBR) was defined as the percentage of subjects with complete response (CR), partial response (PR) or stable disease (SD) as per RECIST 1.1 where Complete Response (CR): disappearance of all target lesions; Partial Response (PR): at least a 30% decrease in the sum of diameters of target lesions; Stable Disease (SD): neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

    Time frame: Every 6 weeks until the date of objectively documented progression for up to 2 years.

  2. Duration of Response (DOR)

    Duration of response (DOR) was defined as the time from date of the first documentation of objective tumor response (CR or PR) to the first documentation of objective progression of disease (PD) as per RECIST 1.1 or to death due to any cause in the absence of documented PD. DOR was calculated only for the subjects achieving a confirmed CR or PR. As per RECIST 1.1, Complete Response (CR): disappearance of all target lesions; Partial Response (PR): at least a 30% decrease in the sum of diameters of target lesions; Progressive Disease (PD): at least a 20% increase in the sum of diameters of target lesions, or the appearance of one or more new lesions.

    Time frame: Every 6 weeks until the date of objectively documented progression for up to 2 years.

  3. Duration of Clinical Benefit

    Duration of clinical benefit (CB) was defined as the time from date of the first documentation of clinical benefit (either CR, PR or SD) to the first documentation of objective progression of disease (PD) as per RECIST 1.1 or to death due to any cause in the absence of documented PD. Duration of clinical benefit was calculated only for the subjects achieving a clinical benefit. As per RECIST 1.1, Complete Response (CR): disappearance of all target lesions; Partial Response (PR): at least a 30% decrease in the sum of diameters of target lesions; Stable Disease (SD): neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; Progressive Disease (PD): at least a 20% increase in the sum of diameters of target lesions, or the appearance of one or more new lesions.

    Time frame: Every 6 weeks until the date of objectively documented progression for up to 2 years.

  4. Duration of Stable Disease

    Duration of stable disease (SD) was defined as the time from the date of the first study treatment to the first documentation of objective progression of disease (PD) as per RECIST 1.1 or to death due to any cause in the absence of documented PD. Duration of stable disease was calculated only for the subjects achieving a stable disease as their best overall response. The best overall response was defined as the best response recorded from the start of the study treatment until the end of study. As per RECIST 1.1, Stable Disease (SD): neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; Progressive Disease (PD): at least a 20% increase in the sum of diameters of target lesions, or the appearance of one or more new lesions.

    Time frame: Every 6 weeks until the date of objectively documented progression for up to 2 years.

  5. Progression Free Survival (PFS)

    Progression-free survival (PFS) was defined as the time from the date of first study treatment to the first documentation of objective progression of disease (PD) as per RECIST 1.1 or to death due to any cause in the absence of documented PD. For subjects who remained alive without progression at the end of the study, the event date was censored at the date of last disease assessment. As per RECIST 1.1, Progressive Disease (PD): at least a 20% increase in the sum of diameters of target lesions, or the appearance of one or more new lesions.

    Time frame: Every 6 weeks until the date of objectively documented progression for up to 2 years.

  6. Overall Survival (OS)

    Overall survival (OS) was defined as the time from date of first study treatment to death due to any cause. For surviving subjects at the end of the study, the OS endpoint was censored at the date of last contact (or last date known to be alive).

    Time frame: From the start of study treatment up to the date of death or date of last contact for up to 3 years.

07

Results

Posted Apr 6, 2025

Participant flow

Participant flow — Overall Study
MilestoneAB-16B5 12 mg/kg & Docetaxel 75 mg/m2
Started35
Completed0
Not completed35
Withdrew: Disease progression20
Withdrew: Adverse event5
Withdrew: Physician decision4
Withdrew: Death3
Withdrew: Other2
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryObjective Response Rate (ORR)

Objective response rate (ORR) was defined as the percent of subjects documented to have a confirmed complete response (CR) or partial response (PR) as per RECIST 1.1 where Complete Response (CR): disappearance of all target lesions; Partial Response (PR): at least a 30% decrease in the sum of diameters of target lesions.

Time frame:
Every 6 weeks until the date of objectively documented progression for up to 2 years.
Reported as:
Count of participants · Participants
Objective Response Rate (ORR)
ParticipantsAB-16B5 12 mg/kg & Docetaxel 75 mg/m2
Objective Response Rate (ORR)6
SecondaryClinical Benefit Rate (CBR)

Clinical benefit rate (CBR) was defined as the percentage of subjects with complete response (CR), partial response (PR) or stable disease (SD) as per RECIST 1.1 where Complete Response (CR): disappearance of all target lesions; Partial Response (PR): at least a 30% decrease in the sum of diameters of target lesions; Stable Disease (SD): neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD.

Time frame:
Every 6 weeks until the date of objectively documented progression for up to 2 years.
Reported as:
Count of participants · Participants
Clinical Benefit Rate (CBR)
ParticipantsAB-16B5 12 mg/kg & Docetaxel 75 mg/m2
Clinical Benefit Rate (CBR)16
SecondaryDuration of Response (DOR)

Duration of response (DOR) was defined as the time from date of the first documentation of objective tumor response (CR or PR) to the first documentation of objective progression of disease (PD) as per RECIST 1.1 or to death due to any cause in the absence of documented PD. DOR was calculated only for the subjects achieving a confirmed CR or PR. As per RECIST 1.1, Complete Response (CR): disappearance of all target lesions; Partial Response (PR): at least a 30% decrease in the sum of diameters of target lesions; Progressive Disease (PD): at least a 20% increase in the sum of diameters of target lesions, or the appearance of one or more new lesions.

Time frame:
Every 6 weeks until the date of objectively documented progression for up to 2 years.
Reported as:
Median · Days
Duration of Response (DOR)
DaysAB-16B5 12 mg/kg & Docetaxel 75 mg/m2
Duration of Response (DOR)283.50 (81.00 to 548.00)
SecondaryDuration of Clinical Benefit

Duration of clinical benefit (CB) was defined as the time from date of the first documentation of clinical benefit (either CR, PR or SD) to the first documentation of objective progression of disease (PD) as per RECIST 1.1 or to death due to any cause in the absence of documented PD. Duration of clinical benefit was calculated only for the subjects achieving a clinical benefit. As per RECIST 1.1, Complete Response (CR): disappearance of all target lesions; Partial Response (PR): at least a 30% decrease in the sum of diameters of target lesions; Stable Disease (SD): neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; Progressive Disease (PD): at least a 20% increase in the sum of diameters of target lesions, or the appearance of one or more new lesions.

Time frame:
Every 6 weeks until the date of objectively documented progression for up to 2 years.
Reported as:
Median · Days
Duration of Clinical Benefit
DaysAB-16B5 12 mg/kg & Docetaxel 75 mg/m2
Duration of Clinical Benefit230.00 (108.00 to 447.00)
SecondaryDuration of Stable Disease

Duration of stable disease (SD) was defined as the time from the date of the first study treatment to the first documentation of objective progression of disease (PD) as per RECIST 1.1 or to death due to any cause in the absence of documented PD. Duration of stable disease was calculated only for the subjects achieving a stable disease as their best overall response. The best overall response was defined as the best response recorded from the start of the study treatment until the end of study. As per RECIST 1.1, Stable Disease (SD): neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD; Progressive Disease (PD): at least a 20% increase in the sum of diameters of target lesions, or the appearance of one or more new lesions.

Time frame:
Every 6 weeks until the date of objectively documented progression for up to 2 years.
Reported as:
Median · Days
Duration of Stable Disease
DaysAB-16B5 12 mg/kg & Docetaxel 75 mg/m2
Duration of Stable Disease255.00 (128.00 to 543.00)
SecondaryProgression Free Survival (PFS)

Progression-free survival (PFS) was defined as the time from the date of first study treatment to the first documentation of objective progression of disease (PD) as per RECIST 1.1 or to death due to any cause in the absence of documented PD. For subjects who remained alive without progression at the end of the study, the event date was censored at the date of last disease assessment. As per RECIST 1.1, Progressive Disease (PD): at least a 20% increase in the sum of diameters of target lesions, or the appearance of one or more new lesions.

Time frame:
Every 6 weeks until the date of objectively documented progression for up to 2 years.
Reported as:
Median · Days
Progression Free Survival (PFS)
DaysAB-16B5 12 mg/kg & Docetaxel 75 mg/m2
Progression Free Survival (PFS)118.00 (47.00 to 231.00)
SecondaryOverall Survival (OS)

Overall survival (OS) was defined as the time from date of first study treatment to death due to any cause. For surviving subjects at the end of the study, the OS endpoint was censored at the date of last contact (or last date known to be alive).

Time frame:
From the start of study treatment up to the date of death or date of last contact for up to 3 years.
Reported as:
Median · Days
Overall Survival (OS)
DaysAB-16B5 12 mg/kg & Docetaxel 75 mg/m2
Overall Survival (OS)234.00 (148.00 to 437.00)

Adverse events

Collected over For up to 3 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
AB-16B5 12 mg/kg & Docetaxel 75 mg/m223/35 (65.7%)23/35 (65.7%)35/35 (100%)
Most frequent serious events
Showing 10 of 35
Most frequent serious events
EventAB-16B5 12 mg/kg & Docetaxel 75 mg/m2
PneumoniaInfections and infestations7/35
HypotensionVascular disorders3/35
DiverticulitisInfections and infestations2/35
Pulmonary embolismRespiratory, thoracic and mediastinal disorders2/35
Pulmonary haemorrhageRespiratory, thoracic and mediastinal disorders2/35
Respiratory failureRespiratory, thoracic and mediastinal disorders2/35
Disease progressionGeneral disorders2/35
AnaemiaBlood and lymphatic system disorders2/35
COVID-19Infections and infestations1/35
Clostridium difficile colitisInfections and infestations1/35
Most frequent other events
Showing 10 of 88
Most frequent other events
EventAB-16B5 12 mg/kg & Docetaxel 75 mg/m2
FatigueGeneral disorders29/35
AlopeciaSkin and subcutaneous tissue disorders25/35
DyspnoeaRespiratory, thoracic and mediastinal disorders19/35
NauseaGastrointestinal disorders17/35
AnaemiaBlood and lymphatic system disorders16/35
DiarrhoeaGastrointestinal disorders16/35
Infusion related reactionInjury, poisoning and procedural complications16/35
NeutropeniaBlood and lymphatic system disorders13/35
PyrexiaGeneral disorders12/35
Decreased appetiteMetabolism and nutrition disorders12/35

Baseline characteristics

Age, Continuous
Age, Continuous(years)AB-16B5 12 mg/kg & Docetaxel 75 mg/m2
Mean63.1 ± 9.50
Sex: Female, Male
Sex: Female, Male(Participants)AB-16B5 12 mg/kg & Docetaxel 75 mg/m2
Female22
Male13
Race (NIH/OMB)
Race (NIH/OMB)(Participants)AB-16B5 12 mg/kg & Docetaxel 75 mg/m2
American Indian or Alaska Native0
Asian1
Native Hawaiian or Other Pacific Islander0
Black or African American1
White31
More than one race0
Unknown or Not Reported2
Region of Enrollment
Region of Enrollment(participants)AB-16B5 12 mg/kg & Docetaxel 75 mg/m2
Canada26
United States9
Histological Classification of NSCLC
Histological Classification of NSCLC(Participants)AB-16B5 12 mg/kg & Docetaxel 75 mg/m2
Adenocarcinoma28
Squamous Cell Lung Cancer6
Adenosquamous1
Eastern Cooperative Oncology Group (ECOG) Score
Eastern Cooperative Oncology Group (ECOG) Score(Participants)AB-16B5 12 mg/kg & Docetaxel 75 mg/m2
011
122
22
08

Study locations

5 sites
  • The University of Texas MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Hôpital Maisonneuve-Rosemont
    Montreal, Quebec H1T 2M4, Canada
  • Centre Hospitalier de l'Université de Montréal (CHUM)
    Montreal, Quebec H2X 3E4, Canada
  • Institut Universitaire de Cardiologie et de Pneumologie de Québec (IUCPQ)
    Québec, Quebec G1V 4G5, Canada
  • Centre Intégré de Santé et de Services Sociaux des Laurentides (Hôpital Régional de St-Jérôme)
    Saint-Jérôme, Quebec J7Z 5T3, Canada
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2021 to primary completion in Dec 2023, 34 months.

Results were first posted in Apr 2025, 1 year 3 months after primary completion.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's 34 months is close to that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 23, 2020
First posted
Apr 28, 2020
StartActual
Feb 23, 2021
Primary completionActual
Dec 31, 2023
CompletionActual
Dec 31, 2023
Results first posted
Apr 6, 2025
Last update
Apr 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04364620
Lead sponsor
Alethia Biotherapeutics
Responsible party
Sponsor
First posted
Apr 28, 2020
Start date
Feb 23, 2021
Primary completion
Dec 31, 2023
Completion
Dec 31, 2023
Results posted
Apr 6, 2025
Last update
Apr 6, 2025

Study contacts

Julie Laurin
study director · Alethia Biotherapeutics Inc.

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sotevtamab

Start the discussion